# 1. Financial Performance ## A. Key Figures * Revenue: $389.7 Mn (QoQ +3.9%, YoY +18.8%) · ₹97 Cr (YoY +21.8%) * EBIT Margin: 15.5% (+150 bps YoY) · EBIT: ₹5,178.1 Cr (YoY +34.8%) * PAT Margin: 12.7% · PAT: ₹4,249.4 Mn (YoY +38.7%) · EPS: ₹27.4 (YoY +36.5%) * RoCE (ex-cash): 43.8% (+510 bps YoY) · Effective Tax Rate: 5% (Q1) * **DSO:** **56 days** billed (↓2 days QoQ) · **20 days** unbilled (↓3 days QoQ) * Cash & Investments: ₹307.8 Mn (as of Jun 30, 2025) · Forward Contracts: $440 Mn (avg. ₹86.90/$) ## B. Revenue Growth * **Resilient Growth Trajectory:** 21st consecutive quarter of growth achieved despite moderation in constant currency sequential expansion. * **Currency Impact:** Constant currency QoQ growth slowed to **3%**, below recent averages, attributed to project timing and macro factors beyond management control. * **Strong USD Performance:** Revenue growth in dollar terms outpaced constant currency, aided by favorable exchange rate movements during the quarter. ## C. Profit Margins * **Margin Expansion with Headwinds:** YoY EBIT margin improved significantly despite sequential pressure from **unfavorable currency**, **higher amortization**, and **project de-risking impacts**. * **Cost Tailwinds & Transients:** Lower ESOP expenses provided a meaningful boost, partially offset by absence of prior-period earn-out reversal benefit. * **Operational Leverage:** PAT growth and RoCE expansion reflect improved capital efficiency and underlying profitability momentum. ## D. Cash Flow * **Exceptional Other Income:** Net other income more than doubled QoQ, driven by **₹87 Cr** in foreign exchange gains from hedge revaluation and credit loss adjustments. * **Healthy Working Capital:** DSO improved across both billed and unbilled categories, signaling stronger collections and execution discipline. * **Cash Conversion:** Operating cash flow was weak relative to PAT, with a conversion ratio of just **6%**, likely influenced by timing and non-operating gains. ## E. Balance Sheet * **Strong Liquidity Position:** Cash and investments increased on better collections, supporting financial flexibility. * **Material Currency Hedges:** Significant forward book of **$440 Mn** at favorable rates provides near-term protection against rupee volatility. --- # 2. Deal Wins & Bookings ## A. Key Figures * TCV: $520.8 Mn (Q) ($337.0 Mn new bookings) * ACV: $385.3 Mn (Q) · $211.8 Mn from new bookings * Book-to-Bill Ratio: 1.3–1.4X (down from 1.5–1.6X) ## B. Contract & Revenue Dynamics * **Divergence in TCV/ACV Signals:** Despite zero new TCV bookings, ACV from new deals reached $8 Mn, indicating a shift toward **shorter-duration or multi-year contracts with front-loaded annual recognition**. * **Focus on Conversion Efficiency:** Management prioritizing improvement in **TCV to ACV conversion ratio**, signaling intent to accelerate revenue realization from existing contract backlog. * **Revenue Visibility:** Near-term revenue supported by **ACV roll-in from prior periods** and **multi-year deal execution**, buffering impact of softer booking trends. ## C. Strategic Wins & Market Positioning * **Flagship Deal Win:** Secured engagement with global clinical research leader to build a **centralized SAE tracking and safety reporting portal**, showcasing domain strength in pharma safety and regulatory compliance. * **Industry Recognition:** Named a **'Leader' in ISG Provider Lens™ 2025 for Digital Engineering**, reinforcing competitive positioning in high-value engineering services. --- # 3. Vertical & Segment Performance ## A. Key Figures * BFSI Growth: **30.7% YoY** (Q1) · Growth accelerated over past 4 quarters * Healthcare & Life Sciences: -2.1% QoQ · +12.4% YoY * Software & Hi-Tech: **+14.1% YoY** * **Emerging Industries:** **+12.4% YoY** ## B. BFSI Growth * **Leadership Position Confirmed:** BFSI emerged as the top-performing vertical with strong double-digit growth acceleration, driven by large deals, AI-led engagements, and platform-led offerings like SASVA and iAURA. * **Strategic Wins Signal Scale:** Landmark co-engineering mandate from a UK-based banking leader underscores Persistent’s growing influence and ability to displace incumbents in digital banking transformation. * **Growth Trajectory Dependent on Execution:** Momentum remains robust, but future performance hinges on pipeline conversion; no guidance beyond current fiscal year. ## C. Healthcare Trends * **Short-Term Headwinds, Long-Term Resilience:** Decline in QoQ revenue attributed to planned onshore-to-offshore transitions and customer-specific ramp-up delays, not sector-wide weakness. * **Strategic Expansion Secured:** Win with a global life sciences leader to establish a software CoE in India highlights governance strength and deepening partnerships despite near-term volatility. * **Growth Moderation Expected:** While pipeline remains healthy across subsegments, YoY growth rates are anticipated to normalize from prior highs of **30–60%**. ## D. Software & Hi-Tech * **Stable Performance with Strategic Upside:** Modest YoY growth masks high-value wins, including legacy modernization for a top global tech firm and a 360-degree engagement with a leader in software quality tools. * **Agentic AI Driving Transformation:** Expansion into AI-native use cases, particularly in cloud testing and product engineering, positions the segment for future scalability. ## E. Emerging Industries * **Solid Growth Foundation:** Emerging Industries delivered low-single-digit YoY growth, reflecting early traction and execution in niche domains. * **Vertical Expansion on Hold:** Strategic focus remains on deepening core verticals over the next **1–3 years**; new sectors like automotive or industrial will be evaluated for organic or inorganic entry post-2025. --- # 4. Geography & Client Mix ## A. Key Figures * Revenue Growth (USD YoY): 17.4% North America · 37.5% Europe · 18.3% India · -1.7% Rest of World * **Top Customer Growth (USD YoY):** **22.8%** top 5 · **20.2%** top 10 · **23.1%** top 20 · **22.7%** top 50 · **22.4%** top 100 * High-Value Client Expansion: **41 → 56** customers in ₹5Mn+ bracket (past year) · **10 → 12** in ₹20Mn+ · **3 → 4** in ₹75Mn+ ## B. Regional Performance * **Europe Leads Growth:** Strongest regional performance with solid **5% year-on-year revenue increase** in USD terms, outpacing other geographies. * **North America & India Show Resilience:** Both regions delivered positive momentum despite macro headwinds, with **modest but stable growth** in USD terms. * **Rest of World Faces Pressure:** Revenue declined **7% year-on-year** in USD, indicating softness in non-core markets. ## C. Client Mix & Concentration Trends * **Broad-Based Client Growth:** Expansion across all high-revenue tiers, including a significant rise in **₹1 crore+ revenue customers**, signaling deepening client relationships. * **Mid-Tier Client Strength:** Notable increase in **₹2 crore+ and ₹5 crore+ clients**, reflecting successful penetration in mid-to-high value segments. * **Top 5 Revenue Flat QoQ:** Despite strong YoY growth, **top 5 customer revenue stalled quarter-on-quarter**, largely due to performance drag from the **largest healthcare client**. * **Double-Digit QoQ Growth in Mid-Tier Buckets:** **6th–10th and 11th–20th customers** delivered **10–12% quarter-on-quarter revenue growth**, highlighting diversification benefits. --- # 5. AI Platform & Innovation ## A. Key Figures * **Patents:** **55+** (up from 35 in Q4 FY25) ## B. SASVA Adoption * **Flagship AI Platform Launch:** Introduction of **SASVA 0**, a generative, deterministic AI platform, streamlines the full software development lifecycle and delivers significant productivity gains. * **Enterprise-Grade & Cost-Efficient:** SASVA enables secure, customizable AI for regulated sectors and operates efficiently on limited GPUs, reducing infrastructure costs and enabling scalable adoption. * **Self-Validating Development Model:** SASVA 0 was built using SASVA itself, demonstrating its self-improving capabilities and internal productivity impact. * **Deal-Centric Differentiation:** SASVA is a key differentiator in client engagements, unlocking new opportunities in product development, modernization, and private equity due diligence, even when not directly adopted. * **Expanding Addressable Market:** Platform drives growth by enabling AI infusion across engineering workflows and winning projects beyond SASVA, including GitHub Copilot implementations. ## C. Agentic AI Solutions * **Industry-Specific Agentic AI:** Persistent has developed tailored agentic solutions on hyperscaler platforms (e.g., Salesforce, Google) for financial services and healthcare, automating complex workflows like loan underwriting and scientific discovery. * **Strategic Focus on AI Readiness:** Dual pivot toward preparing enterprises for product-based AI adoption and building vertical-specific agentic capabilities to transform business processes. ## D. Patents & IP * **Accelerated IP Development:** Patent portfolio expanded to **55+**, covering core AI domains, reflecting deepening innovation in data intelligence, autonomous agents, and security. * **Integrated Digital Trust Layer:** Acquisition of Arrka is fully embedded across platforms, strengthening Responsible AI, security, and governance in AI deployments. ## E. AI for Business * **Tangible Client Impact:** SASVA enabled a capital markets client to rebuild a core risk platform in **under six months**—a process that would have taken over 18 months traditionally—driving faster time-to-market and revenue growth. * **Leadership in AI Transformation:** Clients view Persistent as a leader in AI-driven modernization, helping Fortune 1000 firms overhaul legacy data systems and build custom AI platforms. * **Net Revenue Growth from AI:** Unlike peers facing revenue deflation, Persistent is capturing **net new revenue** through wallet and market share gains, with no observed revenue erosion from AI productivity pass-through. * **End-to-End AI Platform Integration:** Selected by a major US federal corporation to deliver a future-ready debt platform using custom SASVA-based AI use cases, integrating UI/UX, DevOps, and system modernization. --- # 6. Talent & Operating Levers ## A. Key Figures * **Total Headcount:** **25,314** (+1,821 YoY, +746 QoQ) * Trailing 12-Month Attrition Rate: 13.9% (up from 11.9% YoY) ## B. Leadership & Talent Strategy * **Planned Leadership Transition:** Rajiv Nathani to assume role of Chief People Officer on August 1, 2025, as part of a structured succession plan focused on **AI-driven talent transformation**. * **Broad-Based ESOP Penetration:** ESOPs granted to **~80% of employees**, with differentiated grants to **800+ roles**, now embedded in the cost structure and expected to fluctuate over time. ## C. Utilization & Cost Dynamics * **High Utilization Maintained:** Current utilization remains elevated and is viewed as a flexible lever; no near-term reduction planned due to favorable hiring and retention dynamics. * **Cost Flywheel Effect:** As scale expands from $500M to nearly $5B run rate, cost fluctuations are driven by vendor consolidation and onshore subcontracting, with reductions in one area offset by increases elsewhere. ## D. Compensation & Retention Risks * **Wage Hike Delayed:** Annual salary increases postponed by one quarter as a **prudent, cautionary measure** amid uncertain business conditions, with reassessment planned by year-end. * **Attrition Under Watch:** Despite flat reported attrition at 9%, rising turnover and delayed increments pose potential risks to sentiment, though management sees no strong link to wage policy and expects stability based on notice period trends. * **Sector Competition Intensifying:** Increased attrition attributed to broader market dynamics, including rising activity from GCCs and captives set up by product firms, banks, and enterprises. --- # 7. Client & Macro Risks ## A. Decision-Making Delays * **Healthy Pipeline Amid Macro Caution:** Order book remains strong, but broader macroeconomic conditions are extending decision-making cycles across the industry, necessitating a larger pipeline to sustain booking levels. * **Macro Overhang Weighs on Bookings:** Unresolved tariffs and policy uncertainty are prolonging timelines, creating headwinds for near-term bookings and revenue conversion. ## B. Healthcare Cost Pressures * **Client-Led Cost Optimization Underway:** Top healthcare clients are consolidating vendors and shifting projects offshore, resulting in temporary cost overlap but signaling long-term structural cost control. * **Tariff and Funding Risks Mounting:** China-dependent supply chains face stress from potential tariffs, while reduced federal funding (e.g., USAID, DOGE) is dampening university-led research demand. * **Sector Adapting with Plan B Strategies:** Healthcare and life sciences firms are actively diversifying supply chains and building contingency plans, reflecting heightened financial and operational caution. ## C. Regulated Sector Adoption * **Regulated Industries in Experimentation Phase:** Healthcare, life sciences, and banking remain in proof-of-concept mode, with **CISO and IT caution delaying broad platform adoption**. ## D. Geopolitical Uncertainty * **Performance Resilient Despite Geopolitical Noise:** Q1 FY26 results held up amid ongoing uncertainties, including India-Pakistan tensions, Iran developments, and global tariff concerns. * **Hedging Policy Unchanged, Positioning Adjusted:** No change in formal hedge policy; company confirms it actively manages positions within defined limits, with current levels deemed acceptable. --- # 8. Guidance & Outlook ## A. Key Figures * **Revenue Target:** **$2B** by FY27 (Mar-2027) (implies **19%-20% CAGR**) * **Trading Margin Guidance:** **200–300 bps improvement** by FY27 from 7% base * Recent Quarterly Margins: 15.6% and 15% (indicative of progress) ## B. Strategic Priorities & Revenue Trajectory * **Growth with Discipline:** $2B revenue aspiration remains intact, but execution prioritizes **profitable growth over aggressive scaling**, with no urgency to meet the target at any cost. * **AI-Led Momentum:** Company advancing an **AI-led, platform-driven strategy** across AI for Technology and AI for Business, positioning for **top-quartile sector growth** amid improving macro conditions. * **Inorganic Strategy:** Focus on **small, capability-enhancing "tuck-in" acquisitions**; larger deals only in Europe to support **15% revenue target from the region in 2–3 years**. ## C. Margin Outlook & Cost Dynamics * **Margin Path Intact:** Trading margin improvement on track, driven by **pricing optimization, higher utilization, and slower SG&A growth vs. revenue**. * **Near-Term Headwinds Transitory:** Higher onsite costs and deferred wage hikes are temporary; expected to normalize, delivering **future margin benefits** despite ongoing growth investments. * **Prudent Dilution Acceptable:** Willing to accept **slight margin compression** to build capabilities for larger deals, but **no drastic margin sacrifice** for revenue acceleration. ## D. Vertical Performance & Demand Trends * **BFSI Leads Growth:** BFSI remains the **strongest growth vertical**, with sustained momentum expected in key sub-segments. * **Hi-Tech Follows:** Hi-Tech shows solid growth trajectory, outpacing Healthcare. * **Healthcare Stabilizing:** Healthcare to **return to positive growth** this year, though remains the **lowest-growing vertical** post client-related disruptions. * **Cautious Deal Outlook:** No expectation of **near-term deal win windfall**; management emphasizes uncertainty and measured expectations.